Inclusion Criteria

        All of the following inclusion criteria must be fulfilled for eligibility:

          1. Age ≥18 years;

          2. For patients with solid tumors (not unresectable HCC): Patients with histologically
             confirmed diagnosis of locally-advanced, inoperable, metastatic and/or treatment
             refractory solid tumors for whom there are no available therapies that will confer
             clinical benefit;

          3. For patients with unresectable HCC: Patients with histologically confirmed diagnosis
             of locally advanced, inoperable, unresectable HCC who have failed first and second
             lines of therapy and Child-Pugh is A or beyond second line if the performance status
             is preserved and Child-Pugh is A.

          4. Eastern Cooperative Oncology Group Performance status 0-1;

          5. Hemoglobin ≥9.0 g/dL, neutrophil count ≥1.0 x 109/l, platelets ≥100 x 109/L;

          6. Adequate renal function capability, as calculated by creatinine clearance >40 ml/min
             using the Cockroft-Gault formula;

          7. Adequate liver function defined as total bilirubin <1.5 x ULN, and aspartate
             aminotransferase (AST)/alanine aminotransferase (ALT) <3 x ULN. For subjects with
             liver involvement, AST/ALT <5 x ULN; For subjects with liver involvement, AST/ALT <5 x
             ULN;

          8. Measurable disease using clinically appropriate criteria for the type of malignancy,
             RECIST v 1.1 for solid tumors;

          9. Negative blood pregnancy test at the screening visit for women of childbearing
             potential, defined as: female subjects after puberty unless they have been
             postmenopausal for at least two years, are surgically sterile, or are sexually
             inactive and will remain so for the course of the trial;

         10. Willingness to avoid pregnancy and breast feeding beginning two weeks before the first
             TTI-101 dose and ending three months after the last trial treatment. Male subjects
             with female partners of childbearing potential and female subjects of childbearing
             potential must use adequate contraception in the judgment of the Investigator, such as
             a two-barrier method or a one-barrier method with spermicide or intrauterine device
             during trial treatment dosing and for 3 months after the last dose of the study; and

         11. Ability to read and understand the informed consent form and willingness and ability
             to give informed consent and demonstrate comprehension of the trial before undergoing
             any trial activities.

        Exclusion Criteria

        Subjects are ineligible to enroll in this trial if they fulfill any of the following
        exclusion criteria:

          1. Previous therapy with:

               1. Standard therapy including chemotherapy, immunotherapy, biologic therapy, or any
                  other anticancer therapy within 28 days (or five elimination half-lives for
                  non-cytotoxic drugs, whichever is shorter) of Day 1 of trial drug treatment (6
                  weeks for nitrosureas or mitomycin);

               2. Any investigational agent within 28 days of Day 1 of trial drug treatment or 5
                  half-lives for a small molecule/targeted therapy;

          2. Extensive prior radiotherapy on more than 30% of bone marrow reserves, or prior bone
             marrow/stem cell transplantation within 5 years from enrollment; Ongoing toxicity
             (except alopecia) due to a prior therapy, unless returned to baseline or Grade 1 or
             less;

          3. Major surgical intervention or participation in a therapeutic clinical trial within 28
             days from Day 1 of the first dose of TTI-101;

          4. Significantly impaired cardiac function such as unstable angina pectoris, congestive
             heart failure with New York Heart Association (NYHA) class III or IV, myocardial
             infarction within the last 12 months prior to trial entry; signs of pericardial
             effusion, serious arrhythmia (including QTc prolongation of >470 ms and/or pacemaker)
             or prior diagnosis of congenital long QT syndrome or left ventricular ejection
             fraction <50% on screening echocardiogram;

          5. History of cerebral vascular accident or stroke within the previous 2 years;

          6. Uncontrolled hypertension (>160/100mm Hg);

          7. History of Grade 3 or 4 allergic reactions attributed to compounds of similar chemical
             or biologic composition as TTI-101 (hydroxyl-naphthalene sulfonamides);

          8. Known active metastases in the central nervous system (unless stable by brain imaging
             studies for at least 1 month without evidence of cerebral edema and no requirements
             for corticosteroids or anticonvulsants);

          9. History of difficulty swallowing, malabsorption, or other chronic gastrointestinal
             disease or conditions that may hamper compliance and/or absorption of the
             investigational product;

         10. Known human immunodeficiency virus;

         11. Subjects with chronic hepatitis B virus (HBV) infection, unless screening viral load
             <100 IU/mL on stable doses of antiviral therapy. Note: Subjects with chronic HCV
             infection are allowed to enroll in the study but do not have a defined maximum viral
             load requirement for study entry;

         12. Legal incapacity or limited legal capacity;

         13. Pregnant or lactating women;

         14. Any other condition, which in the opinion of the investigator, might impair the
             subject's tolerance of trial treatment, the safety of the individual subject, or the
             outcome of the trial;

         15. Previous treatment of the current malignancy with a STAT inhibitor.